Adaptive Biotechnologies Corp (ADPT) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ADPT currently has 156M outstanding shares. with limited dilution risk as only 10.3M additional shares (6.6%) are authorized for issuance. The company has minimally diluted shareholders by 5.68% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 05, 2026 |
10-Q filing | 155.5M shares outstanding |
160M | 10M |
| Nov 05, 2025 |
10-Q filing | 152.4M shares outstanding |
150M | 10M |
| Aug 05, 2025 |
10-Q filing | 152.1M shares outstanding |
150M | 10M |
| May 01, 2025 |
10-Q filing | 149.2M shares outstanding |
150M | 10M |
| Mar 03, 2025 |
10-K filing | 147.1M shares outstanding |
150M | 10M |
| Nov 07, 2024 |
10-Q filing | 147.5M shares outstanding |
150M | 10M |
| Aug 01, 2024 |
10-Q filing | 147.4M shares outstanding |
150M | 10M |
| May 07, 2024 |
10-Q filing | 145.8M shares outstanding |
150M | 10M |
| Feb 29, 2024 |
10-K filing | 144.4M shares outstanding |
140M | 10M |
| Nov 09, 2023 |
10-Q filing | 144.7M shares outstanding |
140M | 10M |
| Aug 02, 2023 |
10-Q filing | 144.4M shares outstanding |
140M | 10M |
| May 03, 2023 |
10-Q filing | 143.5M shares outstanding |
140M | 10M |
| Feb 14, 2023 |
10-K filing | 142.5M shares outstanding |
140M | 10M |
| Nov 03, 2022 |
10-Q filing | 142.9M shares outstanding |
140M | 10M |
| Aug 03, 2022 |
10-Q filing | 142.4M shares outstanding |
140M | 10M |
| May 04, 2022 |
10-Q filing | 142.2M shares outstanding |
140M | 10M |
| Feb 15, 2022 |
10-K filing | 141.6M shares outstanding |
140M | 10M |
| Nov 03, 2021 |
10-Q filing | 141.1M shares outstanding |
140M | 10M |
| Aug 04, 2021 |
10-Q filing | 140.8M shares outstanding |
140M | 10M |
| May 05, 2021 |
10-Q filing | 140.3M shares outstanding |
140M | 10M |
| Feb 24, 2021 |
10-K filing | 139.2M shares outstanding |
140M | 10M |
| Nov 10, 2020 |
10-Q filing | 136.8M shares outstanding |
140M | 10M |
| Aug 10, 2020 |
10-Q filing | 135.8M shares outstanding |
140M | 10M |
| Jul 16, 2020 |
8-K filing: Adaptive Biotechnologies Corporation entered into an underwriting agreement for a public offering of 8,000,000 shares of common stock at $40.00 per share, with 6,000,000 shares issued by the company and 2,000,000 shares sold by a selling shareholder. ($320.0M proceeds) |
130M | 10M |
| May 12, 2020 |
10-Q filing | 126.9M shares outstanding |
130M | 10M |
| Feb 26, 2020 |
10-K filing | 126.3M shares outstanding |
130M | 10M |
| Jan 22, 2020 |
S-1/A filing: The filing discusses grants and exercises of stock options for both Series E-1 convertible preferred stock and common stock pursuant to the Sequenta Plan and the 2009 Plan, respectively, during the period beginning January 17, 2017 and ending July 1, 2019. |
120M | 10M |
| Jan 21, 2020 |
S-1 filing: This S-1 filing outlines the company's addressable market, competitive strengths, and the offering of common stock by selling shareholders, with an option for underwriters to purchase additional shares. |
120M | 9.2M |